Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2019
Price : $35 *
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Sanofi
- 11 Jun 2019 Results presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 06 Dec 2018 Status changed from recruiting to completed.
- 17 Aug 2018 Planned End Date changed from 1 Oct 2018 to 4 Oct 2018.